ACCUTANE
ISOTRETINOIN
Approval overview ACCUTANE is listed in Drugs@FDA under application 018662 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient ISOTRETINOIN Form and strength CAPSULE;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor HOFFMANN LA ROCHE Submission history Latest submission status date: 2010-10-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview ACCUTANE is listed in Drugs@FDA under application 018662 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient ISOTRETINOIN Form and strength CAPSULE;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor HOFFMANN LA ROCHE Submission history Latest submission status date: 2010-10-22 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.